Research progress of chimeric antigen receptor NK cells in hepatocellular carcinoma
CSTR:
Author:
Affiliation:

Clc Number:

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Cited by
  • |
  • Materials
  • |
  • Comments
    Abstract:

    Hepatocellular carcinoma(HCC)is the most common type of primary liver cancer. The boom in novel immunotherapies has topped the most remarkable progress in HCC treatment in the past decade. As members of the immune system,natural killer(NK) cells play a vital role in anti-tumor immunity. Chimeric antigen receptor(CAR)-NK cell therapy is a new type of tumor immunotherapy, in which NK cells are genetically engineered to specifically recognize tumor-associated antigens to produce more precise and efficient anti -tumor efficacy. Focusing on CAR targets and related immune checkpoints,this review summarizes the challenges and possible solutions for CAR-NK in HCC treatment. Furthermore,it discusses potential strategies for boosting the efficacy of CAR-NK.

    Reference
    Related
    Cited by
Get Citation

刘思远,陈琳,夏安亮,朱明明,孙美玲,孙倍成.嵌合抗原受体NK细胞治疗肝细胞癌的研究进展[J].南京医科大学学报(自然科学版英文版),2023,(5):595-603,647.

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:February 11,2023
  • Revised:
  • Adopted:
  • Online: May 18,2023
  • Published:
Article QR Code